India’s synthetic biology startup StrainX Bioworks raises $13 million to commercialize its biomanufacturing platform
StrainX Bioworks has raised $13 million from investors including Prime Venture Partners and Leo Capital. All three sources confirm that the company focuses on synthetic biology and precision fermentation, and that the funding will be used to expand manufacturing capacity and advance the commercialization of its biomanufacturing platform. However, details on specific products, prior progress, and more granular use of proceeds are either only mentioned by one source or not disclosed.